• Je něco špatně v tomto záznamu ?

Evaluation of collagen/hydroxyapatite electrospun layers loaded with vancomycin, gentamicin and their combination: Comparison of release kinetics, antimicrobial activity and cytocompatibility

T. Suchý, M. Šupová, P. Sauerová, M. Hubálek Kalbáčová, E. Klapková, M. Pokorný, L. Horný, J. Závora, R. Ballay, F. Denk, M. Sojka, L. Vištejnová,

. 2019 ; 140 (-) : 50-59. [pub] 20190502

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044844

The aim of this study was to develop a biodegradable nanostructured electrospun layer based on collagen (COL), hydroxyapatite nanoparticles (HA), vancomycin hydrochloride (V), gentamicin sulphate (G) and their combination (VG) for the treatment of prosthetic joint infections and the prevention of infection during the joint replacement procedure. COL/HA layers containing different amounts of HA (0, 5 and 15 wt%) were tested for the in vitro release kinetics of antibiotics, antimicrobial activity against MRSA, gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis isolates and cytocompatibility using SAOS-2 bone-like cells. The results revealed that the COL/HA layers released high concentrations of vancomycin and gentamicin for 21 days and performed effectively against the tested clinically-relevant bacterial isolates. The presence of HA in the collagen layers was found not to affect the release kinetics of the vancomycin from the layers loaded only with vancomycin or its combination with gentamicin. Conversely, the presence of HA slowed down the release of gentamicin from the COL/HA layers loaded with gentamicin and its combination with vancomycin. The combination of both antibiotics exerted a positive effect on the prolongation of the conversion of vancomycin into its degradation products. All the layers tested with different antibiotics exhibited potential antibacterial activity with respect to both the tested staphylococci isolates and enterococci. The complemental effect of vancomycin was determined against both gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis in contrast to the application of gentamicin as a single agent. This combination was also found to be more effective against MRSA than is vancomycin as a single agent. Importantly, this combination of vancomycin and gentamicin in the COL/HA layers exhibited sufficient cytocompatibility to SAOS-2, which was independent of the HA content. Conversely, only gentamicin caused the death of SAOS-2 independently of HA content and only vancomycin stimulated SAOS-2 behaviour with an increased concentration of HA in the COL/HA layers. In conclusion, COL/HA layers with 15 wt% of HA impregnated with vancomycin or with a combination of vancomycin and gentamicin offer a promising treatment approach and the potential to prevent infection during the joint replacement procedures.

000      
00000naa a2200000 a 4500
001      
bmc19044844
003      
CZ-PrNML
005      
20200114083128.0
007      
ta
008      
200109s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpb.2019.04.021 $2 doi
035    __
$a (PubMed)31055065
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Suchý, Tomáš $u Department of Composites and Carbon Materials, Institute of Rock Structure and Mechanics, Academy of Sciences of the Czech Republic, Prague 8, Czech Republic; Faculty of Mechanical Engineering, Czech Technical University in Prague, Prague 6, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Electronic address: suchyt@irsm.cas.cz.
245    10
$a Evaluation of collagen/hydroxyapatite electrospun layers loaded with vancomycin, gentamicin and their combination: Comparison of release kinetics, antimicrobial activity and cytocompatibility / $c T. Suchý, M. Šupová, P. Sauerová, M. Hubálek Kalbáčová, E. Klapková, M. Pokorný, L. Horný, J. Závora, R. Ballay, F. Denk, M. Sojka, L. Vištejnová,
520    9_
$a The aim of this study was to develop a biodegradable nanostructured electrospun layer based on collagen (COL), hydroxyapatite nanoparticles (HA), vancomycin hydrochloride (V), gentamicin sulphate (G) and their combination (VG) for the treatment of prosthetic joint infections and the prevention of infection during the joint replacement procedure. COL/HA layers containing different amounts of HA (0, 5 and 15 wt%) were tested for the in vitro release kinetics of antibiotics, antimicrobial activity against MRSA, gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis isolates and cytocompatibility using SAOS-2 bone-like cells. The results revealed that the COL/HA layers released high concentrations of vancomycin and gentamicin for 21 days and performed effectively against the tested clinically-relevant bacterial isolates. The presence of HA in the collagen layers was found not to affect the release kinetics of the vancomycin from the layers loaded only with vancomycin or its combination with gentamicin. Conversely, the presence of HA slowed down the release of gentamicin from the COL/HA layers loaded with gentamicin and its combination with vancomycin. The combination of both antibiotics exerted a positive effect on the prolongation of the conversion of vancomycin into its degradation products. All the layers tested with different antibiotics exhibited potential antibacterial activity with respect to both the tested staphylococci isolates and enterococci. The complemental effect of vancomycin was determined against both gentamicin-resistant Staphylococcus epidermidis and Enterococcus faecalis in contrast to the application of gentamicin as a single agent. This combination was also found to be more effective against MRSA than is vancomycin as a single agent. Importantly, this combination of vancomycin and gentamicin in the COL/HA layers exhibited sufficient cytocompatibility to SAOS-2, which was independent of the HA content. Conversely, only gentamicin caused the death of SAOS-2 independently of HA content and only vancomycin stimulated SAOS-2 behaviour with an increased concentration of HA in the COL/HA layers. In conclusion, COL/HA layers with 15 wt% of HA impregnated with vancomycin or with a combination of vancomycin and gentamicin offer a promising treatment approach and the potential to prevent infection during the joint replacement procedures.
650    _2
$a antibakteriální látky $x chemie $x farmakologie $7 D000900
650    _2
$a kostní cementy $x chemie $7 D001843
650    _2
$a buněčné linie $7 D002460
650    _2
$a kolagen $x chemie $7 D003094
650    _2
$a synergismus léků $7 D004357
650    _2
$a hydroxyapatit $x chemie $7 D017886
650    _2
$a Enterococcus faecalis $x účinky léků $7 D013293
650    _2
$a gentamiciny $x chemie $x farmakologie $7 D005839
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a methicilin rezistentní Staphylococcus aureus $x účinky léků $7 D055624
650    _2
$a mikrobiální testy citlivosti $x metody $7 D008826
650    _2
$a infekce spojené s protézou $x mikrobiologie $x prevence a kontrola $7 D016459
650    _2
$a Staphylococcus epidermidis $x účinky léků $7 D013212
650    _2
$a vankomycin $x chemie $x farmakologie $7 D014640
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šupová, Monika $u Department of Composites and Carbon Materials, Institute of Rock Structure and Mechanics, Academy of Sciences of the Czech Republic, Prague 8, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Sauerová, Pavla $u Institute of Pathological Physiology, 1(st) Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Hubálek Kalbáčová, Marie $u Institute of Pathological Physiology, 1(st) Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Klapková, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, 2(nd) Medical School and University Hospital Motol, Prague 5, Czech Republic.
700    1_
$a Pokorný, Marek $u Contipro a.s., R&D Department, Dolni Dobrouc, Czech Republic.
700    1_
$a Horný, Lukáš $u Faculty of Mechanical Engineering, Czech Technical University in Prague, Prague 6, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Závora, Jan $u Clinical Microbiology and ATB Centre, Institute of Medical Biochemistry and Laboratory Diagnostics, 1(st) Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 2, Czech Republic.
700    1_
$a Ballay, Rastislav $u 1(st) Department of Orthopaedics, 1(st) Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic.
700    1_
$a Denk, František $u Department of Composites and Carbon Materials, Institute of Rock Structure and Mechanics, Academy of Sciences of the Czech Republic, Prague 8, Czech Republic.
700    1_
$a Sojka, Martin $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Institute ofMicrobiology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.
700    1_
$a Vištejnová, Lucie $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
773    0_
$w MED00001640 $t European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 140, č. - (2019), s. 50-59
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31055065 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200114083500 $b ABA008
999    __
$a ok $b bmc $g 1483113 $s 1083517
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 140 $c - $d 50-59 $e 20190502 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace